Alemtuzumab

This page contains recent news articles, when available, and an overview of Alemtuzumab but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Alemtuzumab (when available)

Pharmacology and use:
Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations. For treatment of B-cell chronic lymphocytic leukemia

Mechanism Of Action:
Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells.

News Articles on Alemtuzumab

UK charity to test Merck KGaA cancer drug  -  ‎Jan 3, 2010‎
VX) for non Hodgkin's lymphoma, and alemtuzumab, sold as Campath from Bayer AG (BAYGn.DE) and Genzyme Corp (GENZ.O) for chronic lymphocytic leukaemia. ... Reuters

Adult T-cell Leukemia/ Lymphoma: Complexities in Diagnosis and Novel Treatment ...  -  ‎Dec 17, 2009‎
Though alemtuzumab may induce responses in relapsed/refractory T-cell lymphomas,[6] serious infectious complications are common and there is little efficacy ... Cancer Network

Experimental bone marrow treatment appears to reverse sickle cell disease  -  ‎Dec 10, 2009‎
Investigators used a low dose of radiation to the whole body and two drugs, alemtuzumab and sirolimus, to suppress the immune system. ... Scope (blog)

ASH: Flu-Cam Combo Tops Fludarabine Alone for CLL  -  ‎Dec 11, 2009‎
Fludarabine and alemtuzumab have demonstrated single-agent activity in CLL, and some evidence has suggested that the combination of the two agents has ... MedPage Today

Allogeneic hematopoietic stem-cell transplant protocol successful in adult ...  -  ‎Dec 10, 2009‎
A protocol that combines allogeneic hematopoietic stem cell transplantation with total-body irradiation and treatment with alemtuzumab and sirolimus allowed ... HemOncToday

Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease  -  ‎Dec 9, 2009‎
The patients received 300 cGy of total-body irradiation plus alemtuzumab before transplantation, and sirolimus was administered afterward. ... New England Journal of Medicine (subscription)

Treatment Updates  -  ‎Dec 23, 2009‎
...(alemtuzumab) with Fludara and Cytoxan in patients under age 65 with advanced B-cell chronic lymphocytic leukemia receiving their first treatment. ... Curetoday.com (press release)

Drug TherapiesDrug news and recent developments  -  ‎Dec 23, 2009‎
The approval was based on a study in which 42 percent of CLL patients who had progressed on Fludara (fludarabine) and Campath (alemtuzumab) responded to ... Curetoday.com (press release)

Reversing sickle cell disease in adults  -  ‎Dec 14, 2009‎
To achieve this goal, the investigators used a low dose of radiation to the whole body and two drugs, alemtuzumab and sirolimus, to suppress the immune ... WANE

طريقة جديدة لعلاج (�?قر الدم المنجلي) لدى البالغين  -  ‎Dec 10, 2009‎
وأعطى الباحثون - بقيادة كاتب الدراسة الدكتور / جون تيسدال Dr. John Tisdale - عقار alemtuzumab لـ 10 من المرضى تتراوح أعمارهم 16 إلى 45 وعقار alemtuzumab . ... باب

בביה"ח בני ציון יעזרו למצו�? תרופה ללוקמיה  -  ‎Dec 21, 2009‎
...שני חולי�? המטופלי�? במחלקה ישתתפו במחקר שמטרתו להוכיח לקופות החולי�? שהתרופה הנחקרת (alemtuzumab) יכולה להינתן כטיפול בחולי�? הסובלי�? מלוקמיה לימפוציטית כרונית ... mynet

골수�?��?, 겸�? �?혈구병 치료  -  ‎Dec 10, 2009‎
...사�?� 백혈병 치료제로 T세�?� 면역시스템 억제�? 사용�?�는 '알렘투주맵(Alemtuzumab)'과 '시롤리무스(sirolimus)'를 복용케 한 결과 예후가 매우 좋았다고 �?혔다. ... 헬스코리아뉴스

Sichelzellanämie: Stammzellen für Erwachsene  -  ‎Dec 10, 2009‎
Den jetzt erreichten Erfolg führt der Arzt auf die beiden neuen Medikamente zurück, die das Team eingesetzt hatte: Alemtuzumab und Sirolimus. ... NetDoktor.de

„Mini“-Stammzelltransplantation bessert Sichelzellanämie  -  ‎Dec 10, 2009‎
In der jetzt vorgestellten Studie wurden die Patienten (10 Erwachsene im Alter von 16 bis 45 Jahren) über 5 Tage mit Alemtuzumab (gegen CD52-Lymphozyten ... Deutsches Ärzteblatt

GlaxoSmithKline presenta datos clínicos de tres de sus moléculas oncológicas ...  -  ‎Dec 9, 2009‎
...aprobado en Estados Unidos bajo el nombre de ARZERRA™ para el tratamiento de la leucemia linfocítica crónica refractaria a fludarabina y alemtuzumab. ... acceso.com (Comunicado de prensa)

Arzerra for Refractory Leukemia Cleared by the FDA  -  ‎Nov 9, 2009‎
...is indicated to treat patients with chronic lymphocytic leukemia that is resistant to fludarabine and alemtuzumab, the standard treatment options. ... FDA news (subscription)

GSK and Genmab Receive Accelerated Approval for Arzerra  -  ‎Oct 26, 2009‎
The approval is based on results from a pivotal study in which 42% of patients with CLL who were refractory to both fludarabine and alemtuzumab (two ... Reuters

FDA Grants Accelerated Approval to Ofatumumab for Refractory Chronic ...  -  ‎Oct 27, 2009‎
The approval is based on results from a pivotal study in which 42% of patients with CLL who were refractory to both fludarabine and alemtuzumab responded to ... DG News

Genmab Achieves Milestone in Arzerra Collaboration  -  ‎Oct 26, 2009‎
GSK for the FDA approval of Arzerra for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab. ... Reuters

More Tysabri Problems; Time for a Biogen-Idec Credibility Check  -  ‎Oct 30, 2009‎
Currently Natalizumab is the focal point of interest throughout the world, but [that] other new drugs, such as Alemtuzumab or anti-CD20 antibodies may soon ... BNET

Affordable anti-rejection drug effective  -  ‎Oct 19, 2009‎
The scientists looked at the two most common drugs used for induction immunosuppression therapy with kidney and pancreas transplants -- alemtuzumab, ... United Press International

Genmab shares slide as US facility goes up for sale  -  ‎Nov 6, 2009‎
...lymphocytic leukaemia as a treatment for patients who have not responded to Genzyme Corp's Campath (alemtuzumab) or the chemotherapy fludarabine. ... Pharma Times

Genzyme Corporation Q3 2009 Earnings Call Transcript  -  ‎Oct 21, 2009‎
The alemtuzumab for campus MS program is making good progress. We reported on four year results now on the Phase II trial, but we also announced the Phase ... Seeking Alpha (blog)

Lonza wins contract for Genmab/GSK's Arzerra  -  ‎Nov 12, 2009‎
Arzerra was granted accelerated approval in the US on October 26 for use in patients with CLL that is refractory to fludarabine and alemtuzumab. ... Pharmafocus

Alnara Pharmaceuticals Announces Appointment of Lee R. Brettman, M.D., FACP ...  -  ‎Nov 3, 2009‎
...in drug development has led to several approvals of important products including oncology therapies Velcade (bortezomib) and Campath (alemtuzumab). ... Reuters

Genmab to Present Data from Multiple Studies at ASH  -  ‎Nov 11, 2009‎
Ofatumumab is approved in the US for treatment of chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab. Ofatumumab is not approved ... PharmaLive (press release) (subscription)

Summary: - Genmab Announces Results for the Nine Months Period of 2009  -  ‎Nov 10, 2009‎
In October, we received accelerated approval for Arzerra from the FDA for CLL that is refractory to fludarabine and alemtuzumab. The FDA approval triggered ... Ad-Hoc-News (Pressemitteilung)

Genmab/GlaxoSmithKline: first approval for Arzerra  -  ‎Oct 28, 2009‎
...on a pivotal study involving 225 chronic lymphocytic leukemia (CLL) patients who were refractory to both fludarabine and Campath (alemtuzumab; Genzyme). ... Trading Markets (press release)

Genmab to Sell Manufacturing Facility and Cut 300 Jobs  -  ‎Nov 5, 2009‎
...human CD20 antibody, Arzerra™, as a treatment for patients with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab. ... Genetic Engineering News (press release)

Arzerra™ Approved for Refractory Chronic Lymphocytic Leukemia  -  ‎Nov 2, 2009‎
...for treatment of patients with chronic lymphocytic leukemia (CLL) that is refractory to Fludara® (fludarabine) and Campath® (alemtuzumab). ... Cancer Consultants

Week of Nov. 2, 2009: Eli Lilly Opens Biotech Center; Johnson & Johnson ...  -  ‎Nov 5, 2009‎
...from the US Food and Drug Administration for use in patients with chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab. ... Pharmaceutical Technology Magazine

Genzyme: Focusing on Lumizyme Approval  -  ‎Oct 30, 2009‎
I continue to value alemtuzumab in multiple sclerosis as before, but have lowered my probability of success and expected launch year for mipomersen in ... Seeking Alpha (blog)

Genzyme Reports Third-Quarter Financial Results  -  ‎Oct 22, 2009‎
Genzyme's alemtuzumab for multiple sclerosis showed a durable treatment benefit in a review of four-year phase 2 trial data, which was presented at the ... Business Wire (press release)

Sclerosi multipla: il trattamento con Alemtuzumab è efficace ma può comportare ...  -  ‎Oct 21, 2009‎
In un recente studio clinico di fase II, il trattamento con Alemtuzumab si è mostrato efficace in pazienti con forme iniziali di sclerosi multipla ... Fondazione Serono

FDA, GSK/Genmab�?� 백혈병 치료제 허가  -  ‎Oct 28, 2009‎
...기존 약물�?� Genzyme사�?� Campath(alemtuzumab)나 화학요법제 fludarabine�? 반�?�하지 않는 환�? 치료�? 허가한 것�?�다. 알제�?�는 모노�?�로날 항체로 우리 몸�?� 면역 ... 메디포뉴스

GSK y Genmab reciben la aprobación acelerada de la FDA de ARZERRA® para la ...  -  ‎Oct 30, 2009‎
La aprobación se basa en los resultados de un estudio pivotal en el que un 42% de los pacientes con LLC, refractarios tanto a fludarabina como a alemtuzumab ... acceso.com (Comunicado de prensa)

FDA одобри ofatumumab за лечение на рефрактерна хронична лимфоцитна левкеми�? ...  -  ‎Nov 1, 2009‎
одобри ofatumumab (Arzerra, GlaxoSmithKline) за лечение на пациенти �? хронична лимфоцитна левкеми�?, неподдаваща �?е на терапи�? �? fludarabine alemtuzumab. ... DoctorBG.com

GSK 백혈병 치료제 '아제�?�' 승�?�  -  ‎Oct 29, 2009‎
...아제�?�는 플루다�?�빈(fludarabine)과 알렘투주맵(alemtuzumab)으로 치료�? 실패한 만성 림프구성 백혈병 환�? �? 플루다�?�빈로 치료�? 실패한 환�?와 종양�?� 커 알렘투 ... 헬스코리아뉴스

Arzerra® aprovado pela FDA para tratamento da leucemia linfocítica crónica  -  ‎Oct 27, 2009‎
...em doentes que não respondem à terapêutica com Campath® (alemtuzumab) da Genzyme Corp ou com a quimioterapia fludarabina, noticia o site PharmaTimes. ... POP - Portal de Oncologia Portugês

Brand Names/Synonyms:
Alemtuzumab is also known by the following brand names and/or synonymsCampath; Campath (ILEX Pharmaceuticals LP)

Drug Category:
Alemtuzumab is categorized under the following by the FDA: Antineoplastic Agents

Dosage Forms:
Not Available

Absorption:
Not Available

Interactions:
Not Available

Chemical IUPAC Name:
Humanized anti-CD52 antibody

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.